检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:Bhupinder Kaur Russell Rosenblatt Vinay Sundaram
机构地区:[1]Internal Medicine Department,Cedars-Sinai Medical Center,Los Angeles,CA,USA [2]Department of Gastroenterology and Hepatology,Weill Cornell Medicine,New York,NY,USA [3]Department of Gastroenterology and Hepatology and Comprehen-sive Transplant Center,Cedars-Sinai Medical Center,Los Angeles,CA,USA
出 处:《Journal of Clinical and Translational Hepatology》2022年第4期718-725,共8页临床与转化肝病杂志(英文版)
摘 要:Severe alcoholic hepatitis (sAH) is defined by a modified discriminant function ≥32 or model for end-stage liver disease (MELD) >20. Patients with sAH are in an immu-nocompromised state attributed to cirrhosis-related immu-noparesis and corticosteroid use. Individuals with sAH often develop severe infections that adversely impact short-term prognosis. Currently, the corticosteroid prednisolone is the only treatment with proven efficacy in sAH;however, the combination of corticosteroid treatment and altered host defense in sAH has been thought to increase the risk of acquiring of bacterial, opportunistic fungal, and viral infec-tions. Newer studies have shown that corticosteroids do not increase occurrence of infections in those with sAH;unfor-tunately, the lack of response to corticosteroids may instead predispose to infection development. Prompt and appropri-ate antibiotic treatment is therefore essential to improving patient outcomes. This review highlights common infections and risk factors in patients with sAH. Additionally, current diagnostic, therapeutic, and prophylactic strategies in these patients are discussed.
关 键 词:Alcoholic hepatitis INFECTIONS CORTICOSTEROIDS STOPAH Antibiotic treatment ASPERGILLOSIS IMMUNODEFICIENCY Alcoholic liver disease
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.7